2025 CAMPS Summit Selects Merakris Therapeutics’ Scientist with Inaugural “Best Comparative Trial” AwardCellular, Acellular, Matrix-like Products (CAMPs) Summit hosted first awards ceremony, and recognized Merakris Therapeutics’ Scientist in “Best Comparative Trial Award”.
Merakris Therapeutics Announces Open Enrollment for Phase II Clinical Trial of Subcutaneous Injection Drug for the Treatment of Venous Leg UlcerMerakris aims to deliver a first-in-class drug and pioneer a new era within the wound care industry by commercializing regenerative medicine for hard-to-heal wounds
Merakris Therapeutics Introduces Dermacyte® AC Matrix: A Lyophilized Amnion Chorion AllograftMerakris to showcase new Lyophilized Amnion Chorion Allograft at the Fall Symposium for Advanced Wound Care (SAWC) in Las Vegas at booth 440 on October 2-5, 2024.
Merakris Therapeutics Announces FDA Clearance for Part 2 of its Phase II Multicenter Investigational New Drug Study of Dermacyte® LiquidPart 2 of the Phase II multicenter clinical study for the investigational wound care drug, Dermacyte® Amniotic Wound Care Liquid, will begin late 2024
Jonathan Berlent Joins Merakris as SVP, Head of Strategy and OperationsRESEARCH TRIANGLE PARK, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced today that Jonathan Berlent has joined the company as Senior Vice President, Head of Strategy and Operations.
Merakris Therapeutics to Release Final Part 1 Data From Phase 2 Multicenter Investigational Drug Study for Dermacyte® LiquidClinical trial data will be presented at annual Treasure Hunt Podiatry and Wound Conference in Los Angeles, CA, February 24-25
Merakris To Share Data from Fully Enrolled First Part of Two-Part Dermacyte® Liquid Clinical TrialRESEARCH TRIANGLE PARK, N.C., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics announces it has fully enrolled the first part of a two-part clinical trial to evaluate the safety, effectiveness, and administration frequency of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid. The therapy is being studied to treat non-healing venous stasis ulcers (VSUs).
Merakris Announces Nationwide At-Your-Door Autologous Serum Tears ProgramExtends Reach of Therapy for Dry Eye and Other Ocular Surface Disease Symptoms
Wound Healing Technology Company Merakris Adds Two Executives to Leadership TeamRESEARCH TRIANGLE PARK, N.C., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its investigational new drug programs aimed at treating patients with chronic skin and tissue wounds that fail to heal properly.
Merakris Announces Review in Biomedicines Medical Journal Highlights Therapeutic Potential of Cell-Free Amniotic FluidRESEARCH TRIANGLE PARK, N.C., Nov. 29, 2022 (GLOBE NEWSWIRE) -- A review published recently in the international scientific journal Biomedicines highlights the therapeutic benefits of amniotic fluid in restoring, repairing and regenerating damaged tissue across a range of human diseases and disorders.
First Patient Enrolled in Merakris-Sponsored VA Clinical TrialRESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and efficacy of its investigational wound care product, Dermacyte® Amniotic Wound Care Liquid, for the treatment of non-healing venous stasis ulcers.
